Role of Barrett esophagus and lymph node harvest in recurrence of early esophageal adenocarcinoma

Publication date: Available online 3 July 2020Source: The Annals of Thoracic SurgeryAuthor(s): Jun-Feng Wang, Can-Qiong Tian, Qiang-Bo Kan
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research

Related Links:

This study aims to explore the gene signatures shared between BE and EAC based on integrated network analysis. We obtained EAC- and BE-associated microarray datasets GSE26886, GSE1420, GSE37200, and GSE37203 from the Gene Expression Omnibus and ArrayExpress using systematic meta-analysis. These data were accompanied by clinical data and RNAseq data from The Cancer Genome Atlas (TCGA). Weighted gene co-expression network analysis (WGCNA) and differentially expressed gene (DEG) analysis were conducted to explore the relationship between gene sets and clinical traits as well as to discover the key relationships behind the co-...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusions: This single-institution study demonstrated the feasibility of SBRT for locoregional recurrence of esophageal cancer with minimal treatment-related toxicity and high rates of treated tumor control. Prospective studies identifying ideal salvage SBRT candidates for locoregional failure as well as validating its safety are needed.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsAbove all, we concluded that miR-301b was concerned with the progression of EC via regulating DTNA, suggesting that miR-301b and its target gene, DTNA, might serve as predictive biomarkers for EC therapy.
Source: Esophagus - Category: Gastroenterology Source Type: research
Objective: We aimed to determine whether tumor metabolism could be prognostic of cure in L-EAC patients who receive definitive chemoradiation. Summary Background Data: Patients with inoperable localized esophageal adenocarcinoma (L-EAC) often receive definitive chemoradiation; however, biomarkers and/or imaging variables to prognosticate cure are missing. Methods: Two hundred sixty-six patients with L-EAC who had chemoradiation but not surgery were analyzed from the prospectively maintained EAC databases in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center (Tex...
Source: Annals of Surgery - Category: Surgery Tags: ORIGINAL PAPERS Source Type: research
Conclusion: The magnifying endoscopy diagnostic algorithm for gastric cancer may not be useful for esophageal or EGJ adenocarcinomas because of the low visibility of DLs, especially in Siewert type I adenocarcinoma.
Source: Digestive Diseases - Category: Gastroenterology Source Type: research
Publication date: Available online 28 July 2020Source: European Journal of Surgical OncologyAuthor(s): William R.C. Knight, Ricardo McEwen, Ben E. Byrne, Wais Habib, Rebecca Bott, Janine Zylstra, Ula Mahadeva, James A. Gossage, R.C. Fitzgerald, A. Noorani, P.A.W. Edwards, N. Grehan, B. Nutzinger, C. Hughes, E. Fidziukiewicz, S. MacRae, A. Northrop, G. Contino, X. Li, R. de la Rue
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
ConclusionsThe up-regulation ofCD55 andTOP2A, and the down-regulation ofSCNN1B were common to the brushing samples and might serve as molecular biomarkers for identifying EAC in patients with SSBE.Trial registrationUniversity Hospital Medical Information Network (UMIN) (000004004).
Source: Esophagus - Category: Gastroenterology Source Type: research
Opinion statementDespite a decreasing incidence in the USA, gastric cancer is highly prevalent worldwide. Furthermore, gastric cancer remains highly lethal with median survival of less than 1  year for metastatic disease. The backbone of therapy against metastatic gastric cancer remains cytotoxic chemotherapy, but recent advances in the molecular understanding of gastric cancer have renewed hope within that targeted agents can be leveraged to improve survival and reduce toxicity. For ex ample, in patients with human epidermal growth factor-2 (HER2)-positive gastric cancer, the addition of trastuzumab to frontline chem...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: In curatively resected esophageal cancer, both tumor recurrence hazard and hazard for tumor-related death showed distinct, partly bimodal patterns. It could be justified to intensify the surveillance during the first two postoperative years by initiating a close-meshed follow-up to detect and treat tumor recurrence, as early as possible.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractPurposeLymphocyte activation gene-3 (LAG3) is an immunosuppressive checkpoint molecule expressed on T cells. The frequency and distribution of LAG3 expression in oesophageal adenocarcinoma (EAC) is unknown. Aim of the study was the evaluation and distribution of LAG3 on tumour infiltrating lymphocytes (TILs) and correlation with clinico-pathological and molecular data.MethodsWe analysed tumor tissue samples using immunohistochemistry, multi-colour immunofluorescence and mRNA in-situ technology. The analyses were performed on a multi-spot tissue microarray (TMA) with 165 samples, followed by an evaluation on a singl...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cardiovascular & Thoracic Surgery | Esophagus Cancer